Fox Chase Cancer Center Purchases CyberKnife System

Nation's First Cancer Hospital Will Use CyberKnife Radiosurgery to Non-invasively Treat Tumors Throughout the Body

SUNNYVALE, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that Fox Chase Cancer Center in Philadelphia has purchased a CyberKnife(R) Robotic Radiosurgery System. The CyberKnife System at Fox Chase will be the third to be installed in Pennsylvania, and will be housed in a new radiation facility currently under construction in Buckingham, Pa.

Established in 1904 in Philadelphia as the nation's first cancer hospital, Fox Chase is one of the leading cancer research and treatment centers in the United States. Fox Chase houses some of the most sophisticated technology for cancer surgery, radiation and diagnostic imaging.

The CyberKnife System will enable Fox Chase to expand its radiation offerings to patients who may not have been able to tolerate other treatments or have medically inoperable tumors. The CyberKnife System uses its real-time tracking capabilities to deliver with sub-millimeter precision high doses of radiation to tumors, even while they move with respiration. A non-invasive treatment, the CyberKnife System does not require the use of stereotactic frames or painful, uncomfortable respiratory gating techniques. The CyberKnife System also is the first and only robotic radiosurgery system for the treatment of tumors anywhere in the body.

"Fox Chase has a superior reputation for cancer treatment, particularly using radiation, and for its leadership in research to develop new methods for attacking the disease," said Euan S. Thomson, Ph.D., president and CEO of Accuray Incorporated. "We are proud that Fox Chase has recognized the importance of having a dedicated stereotactic radiosurgery device and look forward to working with the Fox Chase research team to continue enhancing the CyberKnife System."

About Fox Chase Cancer Center

Fox Chase Cancer Center is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as the nation's first cancer hospital, Fox Chase became one of the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, treatment, and community outreach. For more information, call 1-888-FOX-CHASE or 1-888-369-2427.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non- invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 145 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the year ended June 30, 2008 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

SOURCE Accuray Incorporated
12/01/2008
CONTACT: Susan Lehman of Rockpoint Public Relations, for Accuray, +1-
510-832-6006, susan@rockpointpr.com; or Stephanie Tomei, Public Relations
Manager, Accuray, +1-408-789-4234, stomei@accuray.com
Web site: http://www.accuray.com